{"id":"NCT02427464","sponsor":"Helixmith Co., Ltd.","briefTitle":"Phase 3 Gene Therapy for Painful Diabetic Neuropathy","officialTitle":"A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04","primaryCompletion":"2019-04","completion":"2019-04","firstPosted":"2015-04-28","resultsPosted":"2022-08-22","lastUpdate":"2025-02-26"},"enrollment":507,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Painful Diabetic Neuropathy","Diabetic Neuropathy, Painful"],"interventions":[{"type":"BIOLOGICAL","name":"Engensis (VM202)","otherNames":[]},{"type":"OTHER","name":"placebo","otherNames":[]}],"arms":[{"label":"Engensis (VM202)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and efficacy of bilateral intramuscular injections of VM202 versus placebo in the treatment of painful diabetic peripheral neuropathy.\n\nA total of 507 of 477 planned participants were randomized in a 2:1 ratio to one of two treatment groups. Note that 500 participants received Investigational product treatment, whereas 7 participants did not receive Investigational product treatment.\n\nTreatments - Engensis (VM202) - 336 Engensis of 318 planned participants\n\nControl - Placebo (VM202 vehicle) - 164 Placebo of 159 planned participants\n\nRandomization were stratified by current use of gabapentin and/or pregabalin.","primaryOutcome":{"measure":"Change in the Average 24 Hour Pain Score From Baseline to Day 90","timeFrame":"The Pain and Sleep Interference diary was completed by participants for at least 5 assessments during a 7-day period at Screening (the mean 24-hour score was the reference/baseline score) and within 14 days prior to Day 90 visit.","effectByArm":[{"arm":"Engensis (VM202)","deltaMin":-1.8,"sd":2.05},{"arm":"Placebo","deltaMin":-1.57,"sd":2.07}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":25,"countries":["United States"]},"refs":{"pmids":["33465273"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":332},"commonTop":["Injection Site Reaction (Grade 1 or 2)","Upper respiratory tract infection","Pain in extremity","Nasopharyngitis","Arthralgia"]}}